悪性リンパ腫に対する CHOP 療法,THP-COP 療法の有害事象と発熱性好中球減少症の危険因子解析
スポンサーリンク
概要
- 論文の詳細を見る
The authors retrospectively reviewed the incidence and severity of adverse events in 45 in-patients with Non-Hodgkin's Lymphoma who had received chemotherapy consisting of rituximab (375mg/m2)and either CHOP[cyclophosphamide: CPA (750mg/m2),adriamycin:ADR (50mg/m2),vincristine : VCR (1.4mg/m2),prednisolone : PSL (100mg/body/day)]or THP-COP[CPA (650mg/m2),pirarubicin (tetrahydropyranyl adriamycin):THP (40mg/m2),VCR (1.0mg/m2),PSL (40mg /m2/day)]at Iwate Prefectural Central Hospital.We also analyzed the risk factors of febrile neutropenia (FN) in patients receiving both chemotherapies.Age and PS were significantly higher in the THP-COP group,and body surface area and a dosage were significantly higher in CHOP group.Regarding hematotoxicity,adverse events defined as grade 3 or 4 in the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v.3.0) were observed with high frequency in both groups.In the THP-COP group,the frequency of anemia of more than grade 3 was significantly higher (52.2%,p<0.05)and the period required to recover from nadir was significantly longer (13.8±7.3 day,p<0.05)The frequencies of the subjective symptoms of constipation and peripheral neuropathy were high in both groups,and that of alopecia of grade 1 was significantly higher (50.0%,p<0.05)in the CHOP group.Low serum albumin levels (odds:0.088,p<0.05)and a fasting blood sugar level of more than 126mg/dL (odds: 12.003,p<0.05)were risk factors for FN in both groups.These results suggest that with regard to FN and other adverse events that may occur during CHOP and THP-COP chemotherapies,great caution should be exercised with respect to blood counts,serum albumin levels and blood glucose levels.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)